Anke van den Berg
prof. dr.
I work as a clinical molecular biologist in the department of Pathology. In this function I supervise and implement advanced molecular diagnostic techniques. Within my research line, I focus on the molecular pathogenesis of B-cell Hodgkin and non-Hodgkin lymphoma. The specific fields of interest are genomic aberrations, genetic susceptibility, and the role of small and long noncoding RNAs. I have several international collaborations and am PI and co-PI in various projects.
MicroRNA profiling of human primary macrophages exposed to dengue virus identifies miRNA-3614-5p as antiviral and regulator of ADAR1 expression
Published in: PLoS Neglected Tropical Diseases
Access to document
10.1371/journal.pntd.0005981
document
Background: Due to the high burden of dengue disease worldwide, a better understanding of the interactions between dengue virus (DENV) and its human host cells is of the utmost importance. Although microRNAs modulate the outcome of several viral infections, their contribution to DENV replication is poorly understood. Methods and principal findings: We investigated the microRNA expression profile of primary human macrophages challenged with DENV and deciphered the contribution of microRNAs to infection. To this end, human primary macrophages were challenged with GFP-expressing DENV and sorted to differentiate between...
Mayra Diosa-Toro, Liliana Echavarría-Consuegra, Jacky Flipse, Geysson Javier Fernández, Joost Kluiver, Anke van den Berg, Silvio Urcuqui-Inchima, Jolanda M Smit
All-in-one RNA-based assay to detect therapeutic biomarkers in lung cancer
Published in: Annals of Oncology
Access to document
10.1093/annonc/mdx508.023
J. Wei, A. Rybczynska, A. van der Wekken, A. Saber, M. Terpstra, E. Schuuring, W. Timens, T. Hiltermann, H. Groen, A. van den Berg, K. Kok
Identification of transforming growth factorbeta-lregulated microRNAs and the microRNAtargetomes in primary lung fibroblasts
Published in: PLoS ONE
Access to document
10.1371/journal.pone.0183815
document
BACKGROUND: Lung fibroblasts are involved in extracellular matrix homeostasis, which is mainly regulated by transforming growth factor-beta (TGF-β), and are therefore crucial in lung tissue repair and remodeling. Abnormal repair and remodeling has been observed in lung diseases like COPD. As miRNA levels can be influenced by TGF-β, we hypothesized that TGF-β influences miRNA expression in lung fibroblasts, thereby affecting their function. MATERIALS AND METHODS: We investigated TGF-β1-induced miRNA expression changes in 9 control primary parenchymal lung fibroblasts using miRNA arrays. TGF-β1-induced miRNA expression changes were validated and...
Jennie Ong, Wim Timens, Vijay Rajendran, Arjan Algra, Avrum Spira, Marc E Lenburg, Joshua D Campbell, Maarten van den Berge, Dirkje S Postma, Anke van den Berg, Joost Kluiver, Corry-Anke Brandsma
Target gene identification of TGF-beta-induced miR-455-3p and miR-21-3p in lung fibroblasts
Published in: European Respiratory Journal
Access to document
10.1183/1393003.congress-2017.PA1025
Jennie Ong, Wim Timens, Vijay Rajendran, Arjan Algra, Avrum Spira, Marc Lenburg, Joshua Campbell, Maarten van den Berge, Dirkje Postma, Anke van den Berg, Joost Kluiver, Corry-Anke Brandsma
Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression
Published in: PLoS ONE
Access to document
10.1371/journal.pone.0182885
document
Purpose: To determine survival in afatinib-treated patients after treatment with first-generation EGFR tyrosine kinase inhibitors (TKIs) and to study resistance mechanisms in afatinib-resistant tumors. Methods: Characteristics and survival of patients treated with afatinib after resistance to erlotinib or gefitinib in two large Dutch centers were collected. Whole exome sequencing (WES) and pathway analysis was performed on available pre-and post-afatinib tumor biopsies and normal tissue. Results: A total of 38 patients were treated with afatinib. T790M mutations were identified in 22/29 (76%) pre-afatinib treatment tumor samples. No difference in median progression-free-survival (2.8...
A. J. van der Wekken, J. L. Kuiper, A. Saber, M. M. Terpstra, J. Wei, T. J. N. Hiltermann, E. Thunnissen, D. A. M. Heideman, W. Timens, E. Schuuring, K. Kok, E. F. Smit, A. van den Berg, H. J. M. Groen